Show simple item record

dc.contributor.authorGarland, Anne
dc.date.accessioned2017-09-20T15:52:02Z
dc.date.available2017-09-20T15:52:02Z
dc.date.issued2014
dc.identifier.citationHollinghurst, S., Carroll, F., Abel, A., Campbell, J., Garland, A., Jerrom, B., Kessler, D., Kuyken, W., Morrison, J., Ridgway, N., et al. (2014). Cost-effectiveness of cognitive-behavioural therapy as an adjunct to pharmacotherapy for treatment-resistant depression in primary care: Economic evaluation of the CoBalT Trial. The British Journal of Psychiatry, 204 (1), pp.69-76.
dc.identifier.other10.1192/bjp.bp.112.125286
dc.identifier.urihttp://hdl.handle.net/20.500.12904/8582
dc.description.abstractBackground: Depression is expensive to treat, but providing ineffective treatment is more expensive. Such is the case for many patients who do not respond to antidepressant medication.; Aims: To assess the cost-effectiveness of cognitive-behavioural therapy (CBT) plus usual care for primary care patients with treatment-resistant depression compared with usual care alone.; Method: Economic evaluation at 12 months alongside a randomised controlled trial. Cost-effectiveness assessed using a cost-consequences framework comparing cost to the health and social care provider, patients and society, with a range of outcomes. Cost-utility analysis comparing health and social care costs with quality-adjusted life-years (QALYs).; Results: The mean cost of CBT per participant was £910. The difference in QALY gain between the groups was 0.057, equivalent to 21 days a year of good health. The incremental cost-effectiveness ratio was £14 911 (representing a 74% probability of the intervention being cost-effective at the National Institute of Health and Care Excellence threshold of £20 000 per QALY). Loss of earnings and productivity costs were substantial but there was no evidence of a difference between intervention and control groups.; Conclusions: The addition of CBT to usual care is cost-effective in patients who have not responded to antidepressants. Primary care physicians should therefore be encouraged to refer such individuals for CBT.;
dc.description.urihttps://www.cambridge.org/core/journals/the-british-journal-of-psychiatry/article/costeffectiveness-of-cognitivebehavioural-therapy-as-an-adjunct-to-pharmacotherapy-for-treatmentresistant-depression-in-primary-care-economic-evaluation-of-the-cobalt-trial/22971D29C7D672FB6D13AA2E7737CB58
dc.subjectDrug therapy
dc.subjectDepressive disorder
dc.subjectPrimary health care
dc.titleCost-effectiveness of cognitive-behavioural therapy as an adjunct to pharmacotherapy for treatment-resistant depression in primary care: Economic evaluation of the CoBalT Trial
dc.typeArticle


This item appears in the following Collection(s)

Show simple item record